Rituximab MabThera®
The SHIKARI® Rituximab portfolio provides quantitative free-drug measurement, quantitative and qualitative anti-drug-antibody assays, and a target-capture neutralising-antibody assay for human serum or plasma.
Why Rituximab is relevant to biological-drug monitoring research
Rituximab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Rituximab is a chimeric IgG1 monoclonal antibody directed against CD20 on B lymphocytes, producing B-cell depletion through multiple Fc-dependent and complement-mediated mechanisms. Source ↗
Approved Indications
EMA-authorised uses include selected B-cell lymphomas and chronic lymphocytic leukaemia, rheumatoid arthritis, granulomatosis with polyangiitis/microscopic polyangiitis and pemphigus vulgaris. EMA source ↗
Regimen-Specific Peak Exposure
Regulatory-development pharmacokinetic data show substantial regimen-dependent peak concentrations:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Four verified Rituximab research assays
Ligand-binding ELISA for quantitative analysis of free rituximab in human serum or plasma.
Quantitative ELISA for antibodies to rituximab in human serum or plasma, including the assay-specific confirmation-reagent procedure.
Qualitative ELISA for positive or negative assessment of antibodies to rituximab in human serum or plasma according to assay-specific cut-off interpretation.
Target-capture immunoassay for qualitative detection of free neutralising antibodies to rituximab in human serum or plasma.
Verified Specifications at a Glance
| Kit | REF | Mode | Analyte | Sample | Volume | Time | Analytical output | Tests | Shelf life | Storage | Shipping |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHIKARI® Q-RITUX | RIT-FD-RM | Quantitative | Free rituximab | Human serum / plasma | 10 µL | 135 min | LOD 3 ng/mL; LOQ 3 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATR | RIT-QNS-RM | Quantitative | Antibodies to rituximab | Human serum / plasma | 20 µL | 140 min | LOD 7.5 ng/mL; LOQ 10 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® S-ATR | RIT-QLS-RM | Qualitative | Antibodies to rituximab | Human serum / plasma | 20 µL | 140 min | Positive / negative | 96 | 1 year | 2–8°C | 10–30°C |
| SHIKARI® T-CAP NAb™ — Rituximab | RIT-TCAP-NAb-RM | Qualitative | Free neutralising antibodies to rituximab | Human serum / plasma | 10 µL | 140 min | LOD 50 ng/mL; qualitative | 96 | 6 months | 2–8°C | 10–30°C |
Analytical specifications are summarised from the current controlled IFUs and exact official product records. Standard curves are official illustrative product images and must not be used for sample quantification. Follow the link on each assay card for the corresponding product record on matriksbiotek.com.
Match the assay to the research question
Choose among the four assays according to the analytical output required by the study.
Publications Using SHIKARI® Rituximab Kits 7
All journal publications below are drawn from the Matrix Biotek Publications library and are shown newest first. Records are included when the publication database identifies the biological drug and SHIKARI® product use.
Planning a Rituximab research study?
Matrix Biotek can help identify the appropriate Rituximab assay and prepare regional quotation and delivery information. SHIKARI® products are developed and manufactured in Ankara and supported through our European headquarters in Barcelona.